

# 1 Meta-analysis of CYP2C19 and CYP2D6 metabolic activity on antidepressant 2 response from 13 clinical studies

3  
4 Danyang Li, PhD 1,\*, Oliver Pain, PhD 2, Chiara Fabbri, PhD 1,3, Win Lee Edwin Wong 1,4, Chris  
5 Wai Hang Lo 1, Stephan Ripke, PhD 5,6, Annamaria Cattaneo, PhD 7,8, Daniel Souery, PhD 9, Mojca  
6 Z. Dernovsek, MF 10, Neven Henigsberg, PhD 11, Joanna Hauser, PhD 12, Glyn Lewis, PhD 13, Ole  
7 Mors, PhD 14, Nader Perroud, MD 15, Marcella Rietschel, MD 16, Rudolf Uher, MD 17, Wolfgang  
8 Maier, MD 18, Katherine J. Aitchison, PhD 19, Bernhard T. Baune, MD 20,21,22, Joanna M. Biernacka,  
9 PhD 23,24, Guido Bondolfi, MD 15, Katharina Domschke, MD 25, Masaki Kato, PhD 26, Yu-Li Liu,  
10 PhD 27, Alessandro Serretti, PhD 3, Shih-Jen Tsai, MD 28,29, Richard Weinshilboum, MD 30, the  
11 GSRD Consortium, the Major Depressive Disorder Working Group of the Psychiatric Genomics  
12 Consortium, Andrew M. McIntosh, MD 31, Cathryn M. Lewis, PhD 1,32, \*

- 13  
14 1 = Social, Genetic and Developmental Psychiatry Centre, King's College London, London, GB  
15 2 = Maurice Wohl Clinical Neuroscience Institute, Department of Basic and Clinical Neuroscience, Institute of  
16 Psychiatry, Psychology and Neuroscience, King's College London, London, GB  
17 3 = Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, IT  
18 4 = Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore,  
19 Singapore, SG  
20 5 = Department of Psychiatry and Psychotherapy, Universitätsmedizin Berlin Campus Charité Mitte, Berlin, DE  
21 6 = Analytic and Translational Genetics Unit, Massachusetts General Hospital, Boston, MA, US  
22 7 = Biological Psychiatry Laboratory, IRCCS Fatebenefratelli, Brescia, IT  
23 8 = Department of Pharmacological and Biomedical Sciences, University of Milan, Milan, IT  
24 9 = Laboratoire de Psychologie Medicale, Université Libre de Bruxelles and Psy Pluriel, Centre Européen de  
25 Psychologie Medicale, Brussels, BE  
26 10 = University Psychiatric Clinic, University of Ljubljana, Ljubljana, SI  
27 11 = Department of Psychiatry, Croatian Institute for Brain Research, University of Zagreb Medical School,  
28 Zagreb, HR  
29 12 = Psychiatric Genetic Unit, Poznan University of Medical Sciences, Poznan, PL  
30 13 = Division of Psychiatry, University College London, London, GB  
31 14 = Psychosis Research Unit, Aarhus University Hospital - Psychiatry, Aarhus, DK  
32 15 = Department of Psychiatry, Geneva University Hospitals, Geneva, CH  
33 16 = Department of Genetic Epidemiology in Psychiatry, Medical Faculty Mannheim, University of Heidelberg,  
34 Central Institute of Mental Health, Mannheim, DE  
35 17 = Department of Psychiatry, Dalhousie University, Halifax, NS, CA  
36 18 = Department of Psychiatry and Psychotherapy, University of Bonn, Bonn, DE  
37 19 = Departments of Psychiatry and Medical Genetics and Neuroscience and Mental Health Institute, University  
38 of Alberta, Edmonton, AB, CA  
39 20 = Department of Psychiatry, University of Münster, Münster, DE  
40 21 = Florey Institute for Neuroscience and Mental Health, University of Melbourne, Melbourne, AU  
41 22 = Department of Psychiatry, Melbourne Medical School, University of Melbourne, Melbourne, AU  
42 23 = Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, USA  
43 24 = Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA  
44 25 = Department of Psychiatry and Psychotherapy, Medical Center, University of Freiburg, Freiburg, DE  
45 26 = Department of Neuropsychiatry, Kansai Medical University, Osaka, JP  
46 27 = Center for Neuropsychiatric Research, National Health Research Institutes, Miaoli, TW  
47 28 = Department of Psychiatry, Taipei Veterans General Hospital, Taipei, TW  
48 29 = Division of Psychiatry, School of Medicine, National Yang-Ming University, Taipei, TW  
49 30 = Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN,  
50 USA  
51 31 = Division of Psychiatry, University of Edinburgh, Edinburgh, GB  
52 32 = Department of Medical & Molecular Genetics, King's College London, London, GB  
53 \* = Corresponding author  
54

**NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.**

55 **Abstract**

56 Cytochrome P450 enzymes including CYP2C19 and CYP2D6 are important for antidepressant  
57 metabolism and polymorphisms of these genes have been determined to predict metabolite levels.  
58 Nonetheless, more evidence is needed to understand the impact of genetic variations on antidepressant  
59 response. In this study, individual data from 13 clinical studies of European and East Asian ancestry  
60 populations were collected. The antidepressant response was clinically assessed as remission and  
61 percentage improvement. Imputed genotype was used to translate genetic polymorphisms to four  
62 metabolic phenotypes (poor, intermediate, normal, and ultrarapid) of CYP2C19 and CYP2D6. The  
63 association of CYP2C19 and CYP2D6 metabolic phenotypes with treatment response was examined  
64 using normal metabolizers as the reference. Among 5843 depression patients, a higher remission rate  
65 was found in CYP2C19 poor metabolizers compared to normal metabolizers at nominal significance  
66 (OR = 1.46, 95% CI [1.03, 2.06],  $p = 0.033$ ) but did not survive after multiple testing correction. No  
67 metabolic phenotype was associated with percentage improvement from baseline. After stratifying by  
68 antidepressants primarily metabolized by CYP2C19 and CYP2D6, no association was found between  
69 metabolic phenotypes and antidepressant response. Metabolic phenotypes showed differences in  
70 frequency, but not effect, between European and East Asian studies. In conclusion, metabolic  
71 phenotypes imputed from genetic variants were not associated with antidepressant response. CYP2C19  
72 poor metabolizers could potentially contribute to antidepressant efficacy with more evidence needed.  
73 Information including side effects, antidepressant dosage, as well as population from different  
74 ancestries could be involved to fully capture the influence of metabolic phenotypes and improve the  
75 power of effect assessment.  
76

## 77 Introduction

78 Antidepressants are the first-line treatment for moderate or severe depression, however efficacy varies,  
79 and side effects are common <sup>1</sup>. Approximately 35% of patients reach remission after treatment with a  
80 single antidepressant and a significant proportion of individuals develop treatment-resistant depression  
81 defined as no remission attained after treatment with two or more antidepressants <sup>2-4</sup>. Even within the  
82 same antidepressant class, treatment responses vary substantially. For example, selective serotonin  
83 reuptake inhibitors (SSRIs), the most widely prescribed antidepressants, could lead to remission in 30-  
84 45% of patients <sup>5</sup>. Differences in response rate may be due to many factors including drug-drug  
85 interactions <sup>6</sup>, depression subtypes <sup>7,8</sup>, comorbidity <sup>9</sup>, smoking <sup>10</sup>, and genetic variation, particularly in  
86 drug metabolism genes.

87  
88 Pharmacogenetics utilizes genetic variation that plays a role in medication action and metabolism to  
89 facilitate individualized prescription, thus improving the treatment efficacy, and reducing undesirable  
90 effects <sup>11</sup>. In antidepressants, current evidence and prescribing guidelines support two cytochrome P450  
91 (CYP) genes (*CYP2C19* and *CYP2D6*) for pharmacogenetic testing <sup>11-14</sup>. Both *CYP2C19* and *CYP2D6*  
92 are highly polymorphic, with genetic haplotypes defined by the star allele nomenclature <sup>15</sup>. These star  
93 alleles can be classified into different metabolic phenotypes: poor metabolizers (PMs), intermediate  
94 metabolizers (IMs), normal metabolizers (NMs), and ultrarapid metabolizers (UMs) according to  
95 Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines <sup>13,14</sup>. Compared to NMs,  
96 PMs and IMs have an increased risk of adverse effects because of a lower metabolism rate and elevated  
97 drug serum concentrations, which may also increase treatment efficacy. UMs, on the other hand,  
98 facilitate the metabolic process to reduce drug exposure and may lead to treatment failure through a  
99 lack of efficacy.

100  
101 Clinical studies have shown that genetic variation in these metabolizing enzymes is clearly associated  
102 with metabolite levels, but the link between genetic variation and treatment response or side effects is  
103 more complicated. For example, in the GENDEP study, *CYP2C19* and *CYP2D6* genotypes were  
104 associated with serum concentration of escitalopram and nortriptyline, but did not predict treatment  
105 response <sup>16</sup>. A meta-analysis of 94 studies assessed the relationship between psychiatric drug exposure  
106 (dose-normalized plasma level) and metabolizing status of *CYP2C19* and *CYP2D6*, observing exposure  
107 differences in escitalopram and sertraline <sup>17</sup>. However, treatment effectiveness of these antidepressants  
108 was not associated with *CYP2C19* genotypes in a large retrospective study based on participant self-  
109 report <sup>18</sup>.

110  
111 Guidelines have been developed for antidepressant use based on *CYP2D6* and *CYP2C19* metabolizing  
112 status. For instance, CPIC guidelines for *CYP2D6*, suggest a 50% dose reduction of fluvoxamine,  
113 paroxetine and most tricyclic antidepressants for PMs, and alternative antidepressants that are not  
114 predominantly metabolized by *CYP2D6* are advised for UMs <sup>13,14</sup>. However, evidence is still accruing  
115 to confirm the role of pharmacogenetic testing to guide antidepressant prescribing <sup>11</sup>. Therefore, further  
116 studies are required to provide additional evidence to reach an agreement on appropriate antidepressant  
117 prescribing based on pharmacogenetic testing of *CYP2C19* and *CYP2D6* in clinical use.

118  
119 In this study, we combined clinical and genetic data from 13 clinical studies, with 5843 participants, to  
120 examine the association of *CYP2C19* and *CYP2D6* metabolic phenotypes with clinically evaluated  
121 treatment response across multiple antidepressants. We investigated whether genotype-determined  
122 PMs, IMs, and UMs of *CYP2C19* and *CYP2D6* showed differential antidepressant efficacy, compared  
123 to NMs. This unique resource provides additional evidence of the relationship between CYP gene

124 metabolic phenotypes and treatment response, and may further determine whether metabolizer status  
125 could add useful information for individualized prescribing of antidepressants.

126

## 127 **Methods**

### 128 **Samples**

129 The clinical studies analysed have been described in detail previously <sup>3</sup>. In brief, 10 studies with  
130 European ancestry and 3 studies from East Asia were included. All participants had a diagnosis of major  
131 depressive disorder (MDD) and received at least one antidepressant, with treatment response collected  
132 at baseline, and for 4-12 weeks post-baseline. We assessed two antidepressant response outcomes of  
133 remission and percentage improvement. Remission was a binary outcome defined as a reduction of the  
134 depression symptoms to a prespecified criteria of the rating scale. Percentage improvement was a  
135 continuous measure calculated from the proportional decrease (or increase) of depression symptom  
136 score from baseline. The percentage improvement was standardized (mean 0, standard deviation 1)  
137 within study to allow comparability of different scales across the studies (e.g. HAMD (Hamilton  
138 Depression Rating Scale), MADRS (Montgomery Åsberg Depression Rating Scale), QIDSC (Quick  
139 Inventory of Depressive Symptomatology)). Demographic and clinical variables of age, sex, MDD  
140 baseline severity and antidepressant prescription information were available in each study  
141 ([Supplementary Table 1](#)).

142 Detailed procedures of genotyping have been reported elsewhere <sup>19-27</sup>. Quality control and  
143 imputation were processed using the standard ‘RICOPILI’ pipeline from the Psychiatric Genomics  
144 Consortium (PGC) with 1000 Genomes Project multi-ancestry reference panel <sup>28</sup>. Each step was  
145 performed separately in European and East Asian ancestry studies following standard PGC protocols.  
146 Study details can be found in [Supplementary Table 1](#) and the previous study <sup>3</sup>.

147

### 148 **Star alleles and metabolic phenotypes**

149 Using best guess imputed genotype calls, phasing was conducted separately on the genetic regions of  
150 *CYP2C19* and *CYP2D6* obtained from PharmGKB (<https://www.pharmgkb.org/>). The haplotype was  
151 determined in each sample using SHAPEIT4 software and the 1000 Genomes Project multi-ancestry  
152 reference panel <sup>29</sup>. To fully utilize phased SNPs and translate them to star alleles, we first extracted all  
153 SNPs used to define *CYP2C19* and *CYP2D6* star alleles from the CPIC definition tables  
154 (<https://cpicpgx.org/>; downloaded June 2022). These SNPs were then matched to the phased data, and  
155 matching SNPs were assigned to star alleles following the CPIC guidelines. If a star allele was defined  
156 by more than one SNP, it was counted only when all the defined SNPs were observed. Each star allele  
157 was annotated as having no, decreased, normal, or increased function with corresponding activity value  
158 based on CPIC definition tables and the previous literature ([Supplementary Table 2](#)) <sup>14,30</sup>. The reference  
159 allele (\*1) was assigned to haplotypes that had no annotated functional star alleles or had uncertain or  
160 unknown functional alleles of *CYP2D6*. Because structural variants cannot be determined from  
161 genotype data, *CYP2D6* ultrarapid metabolisers were not included. Next, we calculated the activity  
162 score for each individual by adding the activity values of the two star alleles. Metabolic phenotypes  
163 (PM, IM, NM, UM) were determined following consensus recommendations from the CPIC and the  
164 Dutch Pharmacogenetics Working Group (DPWG) <sup>14,31,32</sup>. In our study, ultrarapid metabolisers were  
165 defined as individuals carrying at least one increased functional allele. To validate the defined metabolic  
166 phenotypes, we compared phenotype concordance with that previously derived in the GENDEP using  
167 Roche AmpliChip CYP450 microarray and TaqMan SNP genotyping <sup>16</sup>. After harmonizing the  
168 metabolizer status, the concordance rate (percentage of individuals assigned the same metabolic  
169 phenotypes) was 96.4% for *CYP2C19* and 79.9% for *CYP2D6* ([Supplementary Table 3](#)).

170

## 171 **Statistical analyses**

### 172 **- Associations**

173 We used the NMs in CYP2C19 and CYP2D6 as the reference group to examine the effect of other  
174 metabolizer groups on antidepressant response. For remission, logistic regression was used to evaluate  
175 the association with CYP2C19 and CYP2D6 metabolic phenotypes in each study, using age, sex, and  
176 MDD baseline severity as covariates. For percentage improvement, linear regression with CYP2C19  
177 and CYP2D6 metabolic phenotypes, adjusting for age and sex, was used to test for association with  
178 metabolic phenotypes. The correlation between MDD baseline score and percentage improvement was  
179 very low (Pearson correlation = 0.042), so we did not add MDD baseline severity as a covariate. We  
180 next stratified into ‘antidepressant groups’, with drugs that were primarily metabolised by either  
181 CYP2C19 or CYP2D6, based on the clinical annotation of Level 1A in PharmGKB<sup>12,33</sup> (Supplementary  
182 Table 4). Stratifying participants by CYP2C19- and CYP2D6-metabolised antidepressants, we repeated  
183 the analyses of remission and percentage improvement in 10 studies with CYP2C19-metabolised  
184 antidepressants (3390 participants) and 6 studies with CYP2D6-metabolised antidepressants (1223  
185 participants) (Supplementary Figure 1).

186

### 187 **- Meta-analyses**

188 In each study, odds ratios (ORs) of remission, and Standard Mean Differences (SMDs, Cohen’s D) of  
189 percentage improvement, with standard errors of both effect sizes, for each metabolizer group were  
190 extracted. We applied random effect meta-analysis since the true effects were assumed to be  
191 heterogeneous due to the difference in factors such as study populations, antidepressants prescribed,  
192 and outcome measurements. The effect sizes in each study were pooled, and inverse-variance weighted.  
193 The between-study heterogeneity was quantified by  $I^2$  statistic and heterogeneity variance  $\tau^2$  using the  
194 Paule-Mandel method for ORs and restricted maximum-likelihood estimator for SMDs. The  
195 significance was tested by Cochran’s Q at  $p < 0.05$ . Additionally, subgroup meta-analyses were applied  
196 to test the hypothesis that effects differed between European and East Asian ancestry. We assumed both  
197 ancestries shared a common between-study heterogeneity ( $\tau^2$ ) due to a small number of studies from  
198 East Asia. Cochran’s Q was used to determine whether the differences between subgroups could be  
199 explained by true effect differences or by sampling errors alone. We performed meta-analyses in all  
200 samples for CYP2C19 and CYP2D6 metabolic phenotypes and then stratified the analyses by  
201 antidepressant groups for the corresponding metabolizer effects. We used  $p$  value  $< 0.05$  as nominal  
202 significance, and corrected for multiple testing for the 5 independent tests of metabolic phenotypes  
203 compared with NMs (3 phenotypes in CYP2C19 and 2 phenotypes in CYP2D6), giving a Bonferroni  
204 corrected  $p$  value of 0.01 (0.05/5). No correction across outcomes (remission and percentage  
205 improvement) was applied, due to their high correlations. All meta-analyses were performed by ‘meta’  
206 package in R 4.2.1.

207 The power of the meta-analysis was calculated by ‘dmetar’ package in R 4.2.1. Using the  
208 sample size of PMs ( $N = 179$ ) and NMs ( $N = 2289$ ) in CYP2C19, the meta-analysis had over 80%  
209 power to detect SMD of 0.074 and OR 1.15 with no effect heterogeneity, or SMD 0.085 and OR 1.17  
210 with low heterogeneity, at a significance level  $p = 0.01$ .

211

### 212 **Sensitivity tests**

213 Three sensitivity analyses were performed. Firstly, each participant’s activity score was calculated as a  
214 continuous measure to assess metabolic activity and compared to the metaboliser groups. We tested  
215 CYP2C19 and CYP2D6 metabolic effects represented by activity scores using the same analyses  
216 described above. For the percentage improvement outcome, correlations were assessed between activity  
217 scores and residuals of percentage improvement after regressing out age and sex, and restricted

218 maximum-likelihood estimator was used to estimate between-study heterogeneity of correlations in the  
219 meta-analyses. Secondly, the impact of baseline depression severity on percentage improvement was  
220 assessed by including it as a covariate in the linear regression analyses. Finally, to test how small studies  
221 might be impacting results, we reran the meta-analysis of CYP2C19 PM on the remission outcome  
222 including only studies with at least 10 PMs present.

223

## 224 **Results**

### 225 **Characteristics of star alleles and metabolic phenotypes**

226 Seven star alleles in *CYP2C19* and 16 alleles in *CYP2D6* were identified from the imputed genotype  
227 data and were classified as having no, decreased, normal and increased function ([Supplementary Table](#)  
228 [2](#)). In general, alleles had similar frequencies in studies of the same ancestry group ([Supplementary](#)  
229 [Figure 2](#)). The reference alleles (\*1) were the most common, with mean frequency 62.8% in *CYP2C19*,  
230 and 39.2% in *CYP2D6* in European ancestry studies, and frequencies of 62.1% and 34.2% in East Asian  
231 studies. Other high frequency alleles in European-ancestry studies were \*17 (22.0%) in *CYP2C19* and  
232 \*4 (19.8%) in *CYP2D6*, while *CYP2C19* \*2 (30.5%) and *CYP2D6* \*10 (48.6%) had high frequencies  
233 in East Asian. A total of 5843 individuals with remission or percentage improvement outcome in 13  
234 studies were analysed. Four metabolizer groups (PM, IM, NM, UM) for CYP2C19 and three  
235 metabolizer groups (PM, IM, and NM) for CYP2D6 were translated from star alleles. In both genes,  
236 the most common metabolizer group was NM, and the rarest was PM ([Table 1](#)). Compared with the  
237 East Asian, the European population had a lower proportion of PM and IM in CYP2C19, and higher  
238 proportion of PM in CYP2D6 ([Figure 1](#), differences between ancestries, Wilcoxon test: CYP2C19 PM  
239  $p = 0.007$ , CYP2C19 IM  $p = 0.007$ , CYP2C19 UM  $p = 0.007$ , CYP2D6 PM  $p = 0.014$ ). For the 12  
240 antidepressants metabolized primarily by either CYP2C19 or CYP2D6, the same distribution of  
241 metabolic phenotypes was found in both antidepressant groups ([Supplementary Table 5](#)).

242

### 243 **Meta-analyses of CYP2C19 and CYP2D6 metabolic phenotypes in all samples**

244 The association of metabolizer status with antidepressant response was first assessed in all samples.  
245 The remission rate and mean percentage improvement in each metabolizer group are presented in [Table](#)  
246 [1](#). Overall, PMs in CYP2C19 showed a higher remission rate with nominal significance (OR = 1.46,  
247 95% CI [1.03, 2.06],  $p = 0.033$ , [Figure 2a](#)) but did not meet correction for multiple testing. The  
248 percentage improvement analysis showed a non-significant higher efficacy in PMs (SMD = 0.13, 95%  
249 CI [-0.03, 0.29],  $p = 0.101$ ). Other metabolic phenotypes in CYP2C19 and CYP2D6 had no difference  
250 from NMs in both outcomes ([Figure 2a](#)). Subgroup meta-analyses found no heterogeneity in the effect  
251 of CYP2C19 PMs in all cohorts or between ancestry groups. In other metabolic phenotypes of both  
252 genes, no significant heterogeneity was detected ([Supplementary Figure 3, 4](#)).

253

### 254 **Meta-analyses of CYP2C19 and CYP2D6 metabolic phenotypes stratified by antidepressant groups**

256 Next, to determine if the metabolic activity was associated with response in antidepressants that were  
257 primarily metabolized by CYP2C19 or CYP2D6<sup>12</sup>, meta-analyses were stratified with 7 CYP2C19-  
258 metabolised antidepressants and 9 for CYP2D6 ([Supplementary Table 4](#)). CYP2C19 PMs showed a  
259 similar trend to the results in all samples, with a higher remission rate and percentage improvement  
260 compared to NMs (remission: OR = 1.47, 95% CI [0.90, 2.39],  $p = 0.121$ ; percentage improvement:  
261 SMD = 0.12, 95% CI [-0.10, 0.34],  $p = 0.282$ , [Figure 2b, c](#)) but the association was not significant.  
262 Other metabolizer groups were not associated with response. Detailed results for each study can be  
263 found in [Supplementary Figures 5 and 6](#). As a comparison, metabolic effect was tested in the  
264 antidepressant groups that were not primarily metabolised by CYP2C19 or CYP2D6. Detailed results  
265 are shown in [Supplementary Figure 7](#).

266  
267  
268  
269  
270  
271  
272  
273  
274  
275  
276  
277  
278  
279  
280  
281

### Sensitivity test

Finally, three sensitivity tests were performed. First, the meta-analyses were repeated using the activity score as a quantitative measurement of metabolic activity to compare the results with the primary analyses. The activity scores differed between European and East Asian studies, with Europeans having higher scores for both CYP2C19 and CYP2D6 (Wilcoxon test: CYP2C19  $p = 0.007$ ; CYP2D6  $p = 0.028$ , [Supplementary Figure 8](#)). However, activity score was not associated with the outcomes of remission or percentage improvement ([Supplementary Table 6](#)). In the second sensitivity test, baseline severity of depression was added as an additional covariate in the analyses of percentage improvement. As in the primary analyses, PMs in CYP2C19 had higher, but non-significant SMD of percentage improvement (SMD = 0.13, 95% CI [-0.03, 0.29],  $p = 0.103$ ). No clear pattern was found in tests of other metabolizers ([Supplementary Table 7](#)). Lastly, we meta-analysed the CYP2C19 PMs for remission by including only studies with more than 10 CYP2C19 PMs. A higher rate of remission was observed in CYP2C19 PMs from 8 studies confirming the association found in the main analyses (OR = 1.56, 95% CI [1.09; 2.24],  $p = 0.016$ ).

### Discussion

In this study, we leveraged 13 clinically defined studies (10 of European-ancestry and 3 from East Asia) to meta-analyse the association of CYP2C19 and CYP2D6 metabolic phenotypes with antidepressant response, using remission and percentage improvement as outcome measures. Using the available imputed genotype data, we identified 7 star alleles of *CYP2C19* and 16 star alleles of *CYP2D6*. We found CYP2C19 PMs had a higher remission rate compared to CYP2C19 NMs in all samples (OR = 1.46; 95% CI [1.03, 2.06]), which reached nominal significance but was not significant at the multiple testing threshold. CYP2C19 PMs also had a higher remission rate in antidepressants primarily metabolised by CYP2C19 (OR = 1.47, 95% CI [0.90, 2.39]) but differences were not significant. No difference in percentage improvement was seen between PMs and NMs. Other metabolizer groups in CYP2C19 and CYP2D6 showed no association with either remission or percentage improvement. Although there were differences in the frequency of star alleles and in the proportions of metabolic phenotypes between European and East Asian studies, the impact of metabolic phenotypes was similar.

Our analysis pipeline for calling star alleles from genotype data detected 7 star alleles of *CYP2C19* including all tier 1 alleles (\*2, \*3 and \*17) and two tier 2 alleles (\*8, \*35) demonstrating a good coverage of imputed genotype for *CYP2C19* region<sup>34</sup>. Nevertheless, only a moderate relationship was detected with CYP2C19 PMs with the remission outcome. Other metabolizer status was not associated with the outcome. When testing the PMs restricted to antidepressants largely metabolised by CYP2C19, a similar effect size was detected but showed no significance, suggesting a loss of power. Other meta-analyses, retrospective studies, and clinical cohorts have replicated a higher antidepressant efficacy of CYP2C19 PMs<sup>18,35-37</sup>. However, a null effect or an opposite association of CYP2C19 slow metabolizers for lower antidepressant efficacy was observed in smaller samples<sup>16,38,39</sup>. This discrepancy may be due to different criteria for study participants, MDD severity, dropout rates, medication prescribed, and lack of information on other associated factors such as antidepressant dosage. Given the heterogeneity of patients and potential confounding variables, our results need further replication to understand the role of CYP2C19 metabolizers under different circumstances. In addition to treatment efficacy, PMs of CYP2C19 were also associated with worse antidepressant tolerability, although these features were not assessed in our study<sup>18,36</sup>. CPIC and the Dutch Pharmacogenetics Working Group (DPWG) have recommended reducing the starting dose of escitalopram, citalopram, and sertraline for CYP2C19 PMs because of the increased probability of adverse effects<sup>14,31</sup>. Appropriate support could be provided to patients at the beginning of the treatment to reduce the dropout rate and maximize the drug effect.

314

315 *CYP2D6* has higher variability and more star alleles than *CYP2C19*, including common, rare, and  
316 structural variants which make genotype analysis more challenging. In our study, 16 star alleles of  
317 *CYP2D6* were classified as having no, decreased, or normal function. No structural variants (such as \*5  
318 allele) could be detected using imputed genotypes, so increased function alleles were not called.  
319 Previous studies have shown that 7% of *CYP2D6* variants were structural variants, so the star allele  
320 calls, diplotype assignment and metabolic phenotype could be affected by missing structural variants  
321 <sup>40,41</sup>. Unlike a previous meta-analysis of clinical trials showing strong associations of *CYP2D6*-guided  
322 antidepressant treatment with improved patient outcomes <sup>42</sup>, we found no association between *CYP2D6*  
323 metabolizer status and treatment outcome in all samples or in the *CYP2D6*-antidepressant group. Thus,  
324 our results should be explained with caution and need to be compared with further studies using  
325 available genotype data.

326

327 Activity score was also applied for the assignment of metabolic phenotype. Using clinical guidelines,  
328 each allele from *CYP2C19* and *CYP2D6* is assigned an activity value and the value is summed across  
329 the two alleles carried to give an activity score representing the individual's metabolic activity <sup>30,32,37</sup>.  
330 We found no effect of activity score on the outcomes of remission and percentage improvement. These  
331 antidepressant results contrast to antipsychotic response, where higher *CYP2C19* activity score was  
332 associated with lower symptom severity <sup>30</sup>. The previous association of *CYP2C19* PMs with remission  
333 outcome was not detected in the activity score analysis. This is likely because PMs have a low frequency  
334 and represent only the lower tail of the activity score distribution, so the effect is diluted when  
335 combining phenotype groups.

336

337 Our analyses included both European and East Asian ancestry populations. The frequencies of star  
338 alleles were clustered by ancestry. For example, European population had lower frequencies of \*2, \*3  
339 in *CYP2C19* and \*10 in *CYP2D6*, but higher frequencies of *CYP2C19* \*17 and *CYP2D6* \*4, than the  
340 East Asian population, leading to fewer PMs and IMs for *CYP2C19* but higher proportions of *CYP2C19*  
341 UMs and *CYP2D6* PMs. These ancestry differences align with the CPIC guideline and other reports  
342 <sup>14,43</sup>. When connecting the cytochrome enzyme status with antidepressant response, few studies have  
343 been performed in the East Asian population. A clinical trial of 100 depression patients from Taipei  
344 found *CYP2D6* intermediate metabolizers had higher frequency of remitters and *CYP2C19* poor  
345 metabolizers had higher serum levels of antidepressants <sup>44</sup>. In some antipsychotics metabolized by  
346 specific cytochrome enzymes, the plasma concentrations of drugs are higher in East Asian populations  
347 than in European populations <sup>45</sup>. In contrast, modelling has suggested that the metabolic contributions  
348 of *CYP2C19* on escitalopram would be similar across European and Asian populations <sup>46</sup>. As there is  
349 little evidence of differentiation by ancestry, current clinical guidelines provide the same antidepressant  
350 dosing recommendations across populations <sup>14</sup>. Our subgroup meta-analyses between the European and  
351 East Asian studies also found no heterogeneity of metabolic effect for both genes but the low sample  
352 size in East Asian studies (9% of all samples) was poorly powered compared to the European studies.

353

354 Some study limitations should be considered. Primarily, larger sample sizes are needed specifically in  
355 different ancestries and drug groups. Even though most studies were of European ancestry, too few  
356 *CYP2C19* PMs (2.1% in European, 3.1% in all participants) were present to show a statistically  
357 significant effect after correcting for multiple testing. Similarly, *CYP2C19* UMs (1.1%) and *CYP2D6*  
358 PMs (< 0.1%) were rare in the East Asian population. Citalopram and escitalopram were the most  
359 prescribed drugs, accounting for 54% of all samples and 93% of the *CYP2C19* antidepressant group,  
360 so the metabolic effect on treatment response was mainly determined by these two drugs. In addition,  
361 no data from clinical evaluations or the environment (e.g. dosage, concomitant drugs, smoking, diet)



362 were analysed, and these factors could influence symptom improvement and cytochrome metabolic  
363 activity. No significant differences between IMs/UMs and NMs could be detected, and higher power is  
364 probably needed to effectively test between metabolizer groups. Side effects were also not available in  
365 our data, which are associated with metabolic phenotypes. We analysed only the final depression score,  
366 at the end of the study treatment, to determine remission and calculate the percentage improvement.  
367 Other studies have suggested using longitudinal measures throughout treatment period as repeated  
368 measures in a mixed linear model to improve the statistical power<sup>38</sup>. Finally, structural variants in  
369 CYP2D6 cannot be detected using genotype data, so no CYP2D6 UMs were identified. Deeper  
370 imputation panels that detect structure variants, or further genetic studies using sequencing or a targeted  
371 array would be necessary for a full assessment of CYP2D6 metaboliser status<sup>47</sup>.

372

373 In conclusion, using imputed genotype data, our meta-analysis showed no significant association  
374 between cytochrome metabolic phenotypes with antidepressant response. Moderate evidence of an  
375 association with CYP2C19 poor metabolizers was indicated, which had higher rates of antidepressant  
376 remission. Metabolic phenotypes differed in frequency between European and East Asian populations,  
377 but did not differ in their effect on treatment outcomes. More samples with patient information and  
378 ancestry diversity could be collected to improve the power and accuracy for a fuller assessment of the  
379 effect of metabolic phenotypes on antidepressant response.

380

### 381 **Acknowledgements**

382 The collection of the sample from the Group for the Study of Resistant Depression (GSRD) Consortium  
383 was supported by an unrestricted grant from Lundbeck for the GSRD. Lundbeck had no further role in  
384 the study design and the collection, analysis, and interpretation of data.

385 The GENDEP (Genome Based Therapeutic Drugs for Depression) study was funded by a European  
386 Commission Framework 6 grant (EC Contract Ref. No. LSHB-CT-2003-503428). H. Lundbeck  
387 provided nortriptyline and escitalopram for the GENDEP study. GlaxoSmithKline and the UK National  
388 Institute for Health Research of the Department of Health contributed to the funding of the sample  
389 collection at the Institute of Psychiatry, London. GENDEP Illumina array genotyping was funded in  
390 part by a joint grant from the UK Medical Research Council and GlaxoSmithKline (Grant No.  
391 G0701420).

392 The GENPOD (GENetic and clinical Predictors Of treatment response in Depression) trial was funded  
393 by the UK Medical Research Council and supported by the UK Mental Health Research Network. The  
394 genotyping of GENPOD samples was supported by the Innovative Medicine Initiative Joint  
395 Undertaking under Grant No. 115008, of which resources are composed of European Union and the  
396 European Federation of Pharmaceutical Industries and Associations (EFPIA) in-kind contribution and  
397 financial contribution from the European Union's Seventh Framework Programme (Grant No.  
398 FP7/2007-2013). EFPIA members Pfizer, GlaxoSmithKline, and F. Hoffmann-La Roche have  
399 contributed work and samples to the project presented here. The PFZ (Pfizer), GSK (GlaxoSmithKline),  
400 and GODS were supported by the Innovative Medicine Initiative Joint Undertaking (IMI-JU) under  
401 Grant No. 115008 of which resources are composed of European Union and EFPIA) in-kind  
402 contribution and financial contribution from the European Union's Seventh Framework Programme  
403 (FP7/2007-2013). EFPIA members Pfizer, GlaxoSmithKline, and F. Hoffmann La-Roche have  
404 contributed work and samples to the project presented here.

405 The PGRN-AMPS (Pharmacogenomics Research Network Antidepressant Medication  
406 Pharmacogenomic Study) study data were obtained via the database of Genotypes and Phenotypes  
407 (dbGAP) (Accession No. phs000670.v1.p1). Funding support for the PGRN-AMPS study was provided  
408 by the National Institute of General Medical Sciences, National Institutes of Health, through the PGRN  
409 grant to Principal Investigators R. Weinshilboum and L. Wang (Grant No. U19 GM61388). D. Mrazek  
410 served as the Principal Investigator for the PGRN-AMPS study within the Mayo Clinic PGRN program.  
411 Genome-wide genotyping was performed at the RIKEN Center for Genomic Medicine, with funding  
412 provided by RIKEN. The datasets used for the analyses described in this manuscript were obtained from  
413 the dbGaP at <http://www.ncbi.nlm.nih.gov/gap/>.

414 Major funding for the Psychiatric Genetics Consortium (PGC) is from the U.S. National Institutes of  
415 Health (Grant Nos. U01 MH109528 and U01 MH109532).  
416 Statistical analyses for the PGC were carried out on the NL Genetic Cluster Computer  
417 (<http://www.geneticcluster.org>) hosted by SURFsara.  
418 For the purposes of open access, the author has applied a Creative Commons Attribution (CC BY)  
419 licence to any Accepted Author Manuscript version arising from this submission.

420

#### 421 **Conflict of Interest**

422 CML has served on the scientific advisory board for Myriad Neuroscience, and is a consultant for UCB.  
423 KJA has received two research grants in the last 2 years from Janssen Inc., Canada (fellowship grants  
424 for trainees), and provided consultancy services in the last three years for Otsuka Canada  
425 Pharmaceutical Inc., Lundbeck Canada, and HLS Therapeutics.

426 AS is or has been consultant/speaker for: Abbott, AbbVie, Angelini, AstraZeneca, Clinical Data,  
427 Boehringer, Bristol Myers Squibb, Eli Lilly, GlaxoSmithKline, InnovaPharma, Italfarmaco, Janssen,  
428 Lundbeck, Naurex, Pfizer, Polifarma, Sanofi, and Servier.

429 AMM has received research support from the Sackler Trust and speakers fees from Janssen and  
430 Illumina.

431 MK has received grant funding from the Japanese Ministry of Health, Labor and Welfare, the Japan  
432 Society for the Promotion of Science, SENSHIN Medical Research Foundation, the Japan Research  
433 Foundation for Clinical Pharmacology and the Japanese Society of Clinical Neuropsychopharmacology  
434 and speaker's honoraria from Sumitomo Pharma, Otsuka, Meiji-Seika Pharma, Eli Lilly, MSD K.K.,  
435 Pfizer, Janssen Pharmaceutical, Shionogi, Mitsubishi Tanabe Pharma, Takeda Pharmaceutical,  
436 Lundbeck Viatrix Inc, Eisai Co., Ltd. and Ono Pharmaceutical and participated in an advisory/review  
437 board for Otsuka, Sumitomo Pharma, Shionogi and Boehringer Ingelheim.

438 DS has received grant/research support from GlaxoSmithKline and Lundbeck; and served as a  
439 consultant or on advisory boards for AstraZeneca, Bristol Myers Squibb, Eli Lilly, Janssen, and  
440 Lundbeck.

441 CF was a speaker for Janssen.

442 NP is or has been consultant/speaker for: Takeda, Janssen and Lundbeck

443 All other authors report no biomedical financial interests or potential conflicts of interest.

444

#### 445 **Funding**

446 This study was supported by the NIMH (MH124873) and by the NIHR Maudsley Biomedical Research  
447 Centre at South London and Maudsley NHS Foundation Trust and King's College London.

448 Chiara Fabbri and Alessandro Serretti were partly supported by #NEXTGENERATIONEU (NGEU),  
449 funded by the Ministry of University and Research (MUR), National Recovery and Resilience Plan  
450 (NRRP), project MNESYS (PE0000006) – A Multiscale integrated approach to the study of the nervous  
451 system in health and disease (DN. 1553 11.10.2022).

452

#### 453 **Data and code availability**

454 Analysis code is available on the github: [https://github.com/DanyangLi107/PGC\\_CYP2gene](https://github.com/DanyangLi107/PGC_CYP2gene).

455

#### 456 **References**

- 457 1. National Institute for Health and Care Excellence. Depression in adults: treatment and  
458 management. NICE guideline NG222. (2022).
- 459 2. Fabbri, C. *et al.* Genetic and clinical characteristics of treatment-resistant depression using primary  
460 care records in two UK cohorts. *Mol. Psychiatry* **26**, 3363–3373 (2021).
- 461 3. Pain, O. *et al.* Identifying the Common Genetic Basis of Antidepressant Response. *Biol. Psychiatry*  
462 *Glob. Open Sci.* **2**, 115–126 (2022).
- 463 4. Trivedi, M. H. *et al.* Evaluation of Outcomes With Citalopram for Depression Using  
464 Measurement-Based Care in STAR\*D: Implications for Clinical Practice. *Am. J. Psychiatry* **163**,  
465 28–40 (2006).

- 466 5. Carvalho, A. F., Cavalcante, J. L., Castelo, M. S. & Lima, M. C. O. Augmentation strategies for  
467 treatment-resistant depression: a literature review: Augmentation strategies for TRD. *J. Clin.*  
468 *Pharm. Ther.* **32**, 415–428 (2007).
- 469 6. Bleakley, S. Antidepressant drug interactions: evidence and clinical significance: Antidepressant  
470 drug interactions. *Prog. Neurol. Psychiatry* **20**, 21–27 (2016).
- 471 7. Fabbri, C., Pain, O., Hagenaaars, S. P., Lewis, C. M. & Serretti, A. Transcriptome-wide association  
472 study of treatment-resistant depression and depression subtypes for drug repurposing.  
473 *Neuropsychopharmacology* **46**, 1821–1829 (2021).
- 474 8. Fava, M. *et al.* Major depressive subtypes and treatment response. *Biol. Psychiatry* **42**, 568–576  
475 (1997).
- 476 9. Iosifescu, D. V., Bankier, B. & Fava, M. Impact of medical comorbid disease on antidepressant  
477 treatment of major depressive disorder. *Curr. Psychiatry Rep.* **6**, 193–201 (2004).
- 478 10. Oliveira, P., Ribeiro, J., Donato, H. & Madeira, N. Smoking and antidepressants  
479 pharmacokinetics: a systematic review. *Ann. Gen. Psychiatry* **16**, 17 (2017).
- 480 11. Bousman, C. A. *et al.* Review and Consensus on Pharmacogenomic Testing in Psychiatry.  
481 *Pharmacopsychiatry* **54**, 5–17 (2021).
- 482 12. Bousman, C. A., Zierhut, H. & Müller, D. J. Navigating the Labyrinth of Pharmacogenetic  
483 Testing: A Guide to Test Selection. *Clin. Pharmacol. Ther.* **106**, 309–312 (2019).
- 484 13. Hicks, J. K. *et al.* Clinical pharmacogenetics implementation consortium guideline (CPIC) for  
485 CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. *Clin.*  
486 *Pharmacol. Ther.* **102**, 37–44 (2017).
- 487 14. Hicks, J. K. *et al.* Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline  
488 for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors.  
489 *Clin. Pharmacol. Ther.* **98**, 127–134 (2015).
- 490 15. Kalman, L. V. *et al.* Pharmacogenetic allele nomenclature: International workgroup  
491 recommendations for test result reporting. *Clin. Pharmacol. Ther.* **99**, 172–185 (2016).
- 492 16. Hodgson, K. *et al.* Genetic differences in cytochrome P450 enzymes and antidepressant  
493 treatment response. *J. Psychopharmacol. (Oxf.)* **28**, 133–141 (2014).
- 494 17. Milosavljević, F. *et al.* Association of CYP2C19 and CYP2D6 Poor and Intermediate  
495 Metabolizer Status With Antidepressant and Antipsychotic Exposure: A Systematic Review and  
496 Meta-analysis. *JAMA Psychiatry* **78**, 270–280 (2021).
- 497 18. Campos, A. I. *et al.* Impact of CYP2C19 metaboliser status on SSRI response: a retrospective  
498 study of 9500 participants of the Australian Genetics of Depression Study. *Pharmacogenomics J.*  
499 **22**, 130–135 (2022).
- 500 19. Baffa, A. *et al.* Norepinephrine and Serotonin Transporter Genes: Impact on Treatment  
501 Response in Depression. *Neuropsychobiology* **62**, 121–131 (2010).
- 502 20. Baune, B. T. *et al.* Association of the COMT val158met Variant with Antidepressant  
503 Treatment Response in Major Depression. *Neuropsychopharmacology* **33**, 924–932 (2008).
- 504 21. Biernacka, J. M. *et al.* The International SSRI Pharmacogenomics Consortium (ISPC): a  
505 genome-wide association study of antidepressant treatment response. *Transl. Psychiatry* **5**, e553  
506 (2015).
- 507 22. Domschke, K. *et al.* Monoamine oxidase A variant influences antidepressant treatment  
508 response in female patients with Major Depression. *Prog. Neuropsychopharmacol. Biol.*  
509 *Psychiatry* **32**, 224–228 (2008).
- 510 23. Fabbri, C. *et al.* Genome-wide association study of treatment-resistance in depression and  
511 meta-analysis of three independent samples. *Br. J. Psychiatry* **214**, 36–41 (2019).
- 512 24. Garriock, H. A. *et al.* A Genome-Wide Association Study of Citalopram Response in Major  
513 Depressive Disorder. *Biol. Psychiatry* **67**, 133–138 (2010).
- 514 25. Mrazek, D. A. *et al.* Treatment Outcomes of Depression: The Pharmacogenomic Research  
515 Network Antidepressant Medication Pharmacogenomic Study. *J. Clin. Psychopharmacol.* **34**, 313–  
516 317 (2014).
- 517 26. Tansey, K. E. *et al.* Genetic Predictors of Response to Serotonergic and Noradrenergic  
518 Antidepressants in Major Depressive Disorder: A Genome-Wide Analysis of Individual-Level  
519 Data and a Meta-Analysis. *PLoS Med.* **9**, (2012).

- 520 27. Uher, R. *et al.* Genome-wide pharmacogenetics of antidepressant response in the GENDEP  
521 project. *Am. J. Psychiatry* **167**, 555–564 (2010).
- 522 28. Lam, M. *et al.* RICOPILI: Rapid Imputation for COnsortias PIpeLIne. *Bioinformatics* **36**,  
523 930–933 (2020).
- 524 29. Delaneau, O., Zagury, J.-F., Robinson, M. R., Marchini, J. L. & Dermitzakis, E. T. Accurate,  
525 scalable and integrative haplotype estimation. *Nat. Commun.* **10**, 5436 (2019).
- 526 30. Okhuijsen-Pfeifer, C. *et al.* Genome-wide association analyses of symptom severity among  
527 clozapine-treated patients with schizophrenia spectrum disorders. *Transl. Psychiatry* **12**, 145  
528 (2022).
- 529 31. Brouwer, J. M. J. L. *et al.* Dutch Pharmacogenetics Working Group (DPWG) guideline for  
530 the gene-drug interaction between CYP2C19 and CYP2D6 and SSRIs. *Eur. J. Hum. Genet.* (2021)  
531 doi:10.1038/s41431-021-01004-7.
- 532 32. Caudle, K. E. *et al.* Standardizing CYP2D6 Genotype to Phenotype Translation: Consensus  
533 Recommendations from the Clinical Pharmacogenetics Implementation Consortium and Dutch  
534 Pharmacogenetics Working Group. *Clin. Transl. Sci.* **13**, 116–124 (2020).
- 535 33. Whirl-Carrillo, M. *et al.* An Evidence-Based Framework for Evaluating Pharmacogenomics  
536 Knowledge for Personalized Medicine. *Clin. Pharmacol. Ther.* **110**, 563–572 (2021).
- 537 34. Pratt, V. M. *et al.* Recommendations for Clinical CYP2C19 Genotyping Allele Selection: A  
538 Report of the Association for Molecular Pathology. *J. Mol. Diagn.* **20**, 269–276 (2018).
- 539 35. Calabrò, M. *et al.* Metabolizing status of CYP2C19 in response and side effects to  
540 medications for depression: Results from a naturalistic study. *Eur. Neuropsychopharmacol.* **56**,  
541 100–111 (2022).
- 542 36. Fabbri, C. *et al.* Effect of cytochrome CYP2C19 metabolizing activity on antidepressant  
543 response and side effects: Meta-analysis of data from genome-wide association studies. *Eur.*  
544 *Neuropsychopharmacol.* **28**, 945–954 (2018).
- 545 37. Mrazek, D. A. *et al.* CYP2C19 Variation and Citalopram Response. *Pharmacogenet.*  
546 *Genomics* **21**, 1–9 (2011).
- 547 38. Islam, F. *et al.* Effects of CYP2C19 and CYP2D6 gene variants on escitalopram and  
548 aripiprazole treatment outcome and serum levels: results from the CAN-BIND 1 study. *Transl.*  
549 *Psychiatry* **12**, 366 (2022).
- 550 39. Joković, D. *et al.* CYP2C19 slow metabolizer phenotype is associated with lower  
551 antidepressant efficacy and tolerability. *Psychiatry Res.* **312**, 114535 (2022).
- 552 40. Del Tredici, A. L. *et al.* Frequency of CYP2D6 Alleles Including Structural Variants in the  
553 United States. *Front. Pharmacol.* **9**, 305 (2018).
- 554 41. Pratt, V. M. *et al.* Recommendations for Clinical CYP2D6 Genotyping Allele Selection: A  
555 Joint Consensus Recommendation of the Association for Molecular Pathology, College of  
556 American Pathologists, Dutch Pharmacogenetics Working Group of the Royal Dutch Pharmacists  
557 Association, and the European Society for Pharmacogenomics and Personalized Therapy. *J. Mol.*  
558 *Diagn.* **23**, 1047–1064 (2021).
- 559 42. Arnone, D. *et al.* Effectiveness of pharmacogenomic tests including CYP2D6 and CYP2C19  
560 genomic variants for guiding the treatment of depressive disorders: Systematic review and meta-  
561 analysis of randomised controlled trials. *Neurosci. Biobehav. Rev.* **144**, 104965 (2023).
- 562 43. Zhou, Y., Ingelman-Sundberg, M. & Lauschke, V. M. Worldwide Distribution of Cytochrome  
563 P450 Alleles: A Meta-analysis of Population-scale Sequencing Projects. *Clin. Pharmacol. Ther.*  
564 **102**, 688–700 (2017).
- 565 44. Tsai, M.-H. *et al.* Genetic polymorphisms of cytochrome P450 enzymes influence metabolism  
566 of the antidepressant escitalopram and treatment response. *Pharmacogenomics* **11**, 537–546  
567 (2010).
- 568 45. Lin, S.-K. Racial/Ethnic Differences in the Pharmacokinetics of Antipsychotics: Focusing on  
569 East Asians. *J. Pers. Med.* **12**, 1362 (2022).
- 570 46. Zhou, L. *et al.* Assessing pharmacokinetic differences in Caucasian and East Asian (Japanese,  
571 Chinese and Korean) populations driven by CYP2C19 polymorphism using physiologically-based  
572 pharmacokinetic modelling. *Eur. J. Pharm. Sci.* **139**, 105061 (2019).
- 573 47. McInnes, G. *et al.* Pharmacogenetics at Scale: An Analysis of the UK Biobank. *Clin.*  
574 *Pharmacol. Ther.* **109**, 1528–1537 (2021).
- 575

**Figure legends:**

Figure 1. Proportion of metabolic phenotypes in each cohort


Figure 2. Association of CYP2C19 and CYP2D6 metabolizer status with antidepressant outcomes

**Table 1. Sample characteristics**

	<b>CYP2C19</b>				<b>CYP2D6</b>		
	<b>Poor (N=179)</b>	<b>Intermediate (N=1601)</b>	<b>Normal (N=2289)</b>	<b>Ultrarapid (N=1774)</b>	<b>Poor (N=249)</b>	<b>Intermediate (N=2087)</b>	<b>Normal (N=3507)</b>
Remission	89 (49.7%)	607 (37.9%)	885 (38.7%)	662 (37.3%)	96 (38.6%)	796 (38.1%)	1351 (38.5%)
Percentage Improvement	0.12 (1.10)	0.00 (0.98)	-0.01 (1.01)	0.00 (0.99)	-0.02 (0.98)	0.01 (0.98)	0.00 (1.00)
Age	45.15 (14.53)	44.76 (14.64)	44.44 (14.19)	44.95 (14.17)	43.41 (14.62)	44.51 (14.29)	44.91 (14.31)
Sex (Female)	112 (62.6%)	987 (61.6%)	1438 (62.8%)	1112 (62.7%)	154 (61.8%)	1301 (62.3%)	2194 (62.6%)
Ancestry (European)	110 (61.5%)	1360 (84.9%)	2078 (90.8%)	1768 (99.7%)	249 (100%)	1902 (91.1%)	3165 (90.2%)
<b>CYP2D6</b>							
Poor	7 (3.9%)	55 (3.4%)	96 (4.2%)	91 (5.1%)	-	-	-
Intermediate	58 (32.4%)	598 (37.4%)	785 (34.3%)	646 (36.4%)	-	-	-
Normal	114 (63.7%)	948 (59.2%)	1408 (61.5%)	1037 (58.5%)	-	-	-

Mean with standard deviation for continuous variables and frequency with proportion for categorical variables were displayed


**Figure 1. Proportion of metabolic phenotypes in each cohort**




DAST: Depression and Sequence of Treatment, GENDEP: Genome Based Therapeutic Drugs for Depression, GENPOD: GENetic and clinical Predictors Of treatment response in Depression, GODS: Geneva Outpatient Depression Study, GSK: Glaxo Smith Kline, GSRD: Group for the Study of Resistant Depression, PFZ: Pfizer, PGRN: Pharmacogenomics Research Network Antidepressant Medication Pharmacogenomic Study, STARD, Sequenced Treatment Alternatives to Relieve Depression.

**Figure 2. Association of CYP2C19 and CYP2D6 metabolizer status with antidepressant outcomes**


a. All samples



b. CYP2C19 antidepressant group



c. CYP2D6 antidepressant group



PM: poor metabolizer, IM: intermediate metabolizer, UM: ultrarapid metabolizer, OR: odd ratio, SMD: standard mean difference, CI: confidence interval